罗格列酮辅助治疗精神分裂症患者使用奥氮平期间的代谢控制：一项为期12周的双盲、安慰剂对照试验。
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.
作者信息
Baptista T, Rangel N, El Fakih Y, Uzcátegui E, Galeazzi T, Beaulieu S, Araujo de Baptista E
机构信息
Department of Physiology, Los Andes University Medical School, Mérida, Venezuela.
出版信息
Pharmacopsychiatry. 2009 Jan;42(1):14-9. doi: 10.1055/s-0028-1085438. Epub 2009 Jan 19.
INTRODUCTION
Excessive body weight gain (BWG), hyperglycemia and dyslipidemia are important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in olanzapine-treated schizophrenia patients.
METHODS
Thirty patients taking olanzapine (10-20 mg daily for 8 months) were randomly allocated to rosiglitazone (n=15; 4 to 8 mg daily) or placebo (n=15) in a 12-week double-blind protocol. Anthropometric and biochemical variables were evaluated at baseline, weeks 6 and 12.
RESULTS
The rosiglitazone and placebo groups gained 3.2+/-4.5 and 2.2+/-2.3 kg, respectively (p=0.65). Insulin and the HOMA-IR significantly decreased after rosiglitazone (p<0.05). Rosiglitazone did not improve the lipid profile, fibrinogen and Hb1c levels.
DISCUSSION
The positive impact of rosiglitazone was limited to improved glycemic control. It cannot be recommended for metabolic control during olanzapine treatment.
引言
体重过度增加（BWG）、高血糖和血脂异常是奥氮平的重要副作用。我们评估了罗格列酮对接受奥氮平治疗的精神分裂症患者的体重增加、胰岛素抵抗指数（HOMA-IR）、血脂、糖化血红蛋白和纤维蛋白原的影响。
方法
30例服用奥氮平（每日10 - 20mg，共8个月）的患者按照12周双盲方案随机分为罗格列酮组（n = 15；每日4 - 8mg）或安慰剂组（n = 15）。在基线、第6周和第12周评估人体测量和生化变量。
结果
罗格列酮组和安慰剂组体重分别增加3.2±4.5kg和2.2±2.3kg（p = 0.65）。罗格列酮治疗后胰岛素和HOMA-IR显著降低（p < 0.05）。罗格列酮未改善血脂、纤维蛋白原和糖化血红蛋白水平。
讨论
罗格列酮的积极作用仅限于改善血糖控制。不建议在奥氮平治疗期间用于代谢控制。
Zotero 插件